Competing endogenous RNA network analysis of CD274, IL‑10 and FOXP3 co‑expression in laryngeal squamous cell

Juan Sun1, Meng Lian1, Hongzhi Ma1

  • 1Department of Otorhinolaryngology Head and Neck Surgery, Beijing Tongren Hospital, Capital Medical University, Beijing 100730, P.R. China.

Molecular Medicine Reports
|December 20, 2017
PubMed

Insights

This study investigated the expression of FOXP3, IL-10, and CD274 in laryngeal squamous cell carcinoma (LSCC), finding they correlate with poor prognosis and may serve as therapeutic targets for immunotherapy.

Area of Science:

  • Oncology
  • Immunology
  • Molecular Biology

Background:

  • Laryngeal squamous cell carcinoma (LSCC) lacks effective molecular therapeutic targets.
  • Understanding immune escape mechanisms in LSCC is crucial for developing new treatments.

Purpose of the Study:

  • To detect the expression of FOXP3, IL-10, and CD274 in LSCC samples.
  • To analyze the association between these molecules and LSCC clinical characteristics and prognosis.
  • To establish a competitive endogenous RNA (ceRNA) network regulating these molecules.

Main Methods:

  • Immunohistochemistry (IHC) was used to detect protein expression in 133 LSCC samples.
  • Statistical analyses included Spearman's rank correlation, Kaplan-Meier, and Cox regression.
  • Bioinformatic databases (StarBase, miRTarBase) were used for ceRNA network construction.

Main Results:

  • High positive expression rates of FOXP3 (68.4%), IL-10 (73.7%), and CD274 (58.6%) were observed.
  • Expression correlated significantly with lymph node metastasis and prognosis (P<0.05).
  • Co-expression of any two proteins was significant (P<0.001), and all three were negatively associated with survival (P<0.05).

Conclusions:

  • FOXP3, IL-10, and CD274 are prognostic risk factors for LSCC.
  • These molecules are implicated in LSCC immune escape mechanisms.
  • The identified ceRNA network provides potential regulatory insights for LSCC immunotherapy development.